Viral vector manufacturing: Breaking the scalability barrier for in-vivo gene therapies
08 Sept 2026
Gene Therapy Development
- Is manufacturing now the primary bottleneck for broader adoption of in-vivo therapies?
- Which challenge is most critical: scalability, cost, analytics, or robustness?
- Which emerging technologies have the greatest potential to transform manufacturing economics?
- How can advanced analytics improve process control and regulatory success?
- How can the industry collectively improve patient access through manufacturing innovation?
Industry Expert
